Teva long-acting olanzapine shows improvements in schizophrenia patients

Teva logo on its USA headquarters building in Parsippany, NJ, USA.

JHVEPhoto/iStock Editorial via Getty Images

Data from a phase 3 trial of Teva Pharmaceutical Industries’ (NYSE:TEVA) TEV-‘749 indicated that the long-acting, subcutaneous version of the antipsychotic olanzapine led to improvement in social functioning and quality of life through week 8.

In addition, no instances of post-injection

Leave a Reply

Your email address will not be published. Required fields are marked *